Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC223510.15690/vramn2235ONCOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ ОНКОЛОГИИReview ArticleSystemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part II. Hematological Markers of InflammationСистемная воспалительная реакция как фактор прогноза при раке молочной железы. Часть II. Гематологические маркеры воспаленияhttps://orcid.org/0000-0001-7406-99737102748586I-2033-20141805-8141SergeevaNatalia S.СергееваНаталья Сергеевна
Russian Federation

PhD in Biology, Professor

д.б.н., профессор

prognoz.01@mail.ruhttps://orcid.org/0000-0002-8017-56576603382243L-3592-20184364-6134KarmakovaTatiana A.КармаковаТатьяна Анатольевна
Russian Federation

PhD in Biology

д.б.н.

kalmar123@yandex.ruhttps://orcid.org/0000-0003-3347-31061134-3930PolyakMarianna A.ПолякМарианна Александровна
Russian Federation

MD

врач-онколог

marianna29@yandex.ruhttps://orcid.org/0000-0002-5920-5823546833463009992-7676AlentovIgor I.АлентовИгорь Игоревич
Russian Federation

PhD in Biology

к.б.н.

igoralentov@yandex.ruP.A. Herzen Moscow Oncology Research InstituteМосковский научно-исследовательский онкологический институт им. П.А. Герцена25122022040220237764084190310202209122022Copyright ©; 2023, "Paediatrician" Publishers LLCCopyright ©; 2023, Издательство "Педиатръ"2023"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/2235

Chronic inflammation is one of the recognized factors contributing to the onset and progression of malignant neoplasms. At the systemic level, a chronic inflammatory process is accompanied by an increased levels of inflammatory mediators and a change in hematological parameters of peripheral blood. According to numerous clinical studies, the change in the ratio of blood cell populations in cancer patients is an independent prognostic factor in malignant tumors of various localizations. This review is devoted to hematological parameters of the systemic inflammatory response (SIR) in breast cancer (BC). The review presents the characteristics of blood cells used for calculations of hematological indices (neutrophils, lymphocytes, monocytes, platelets); approaches for assessing SIR using these indices (NLR, PLR, LMR, etc.); comparative analysis of data on the association of the hematological indices with the clinical and morphological features of BC, patient survival and tumor response to chemotherapy. The data indicating the benefit of SIR hematological markers investigation during monitoring after treatment are summarized. Complex algorithms, including clinical, morphological and hematological factors, which are proposed to improve the quality of prognosis assessment, are considered. The information accumulated to date suggests that hematological indices reflecting SIR activity in BC patients can serve as additional independent prognostic factors. The development of the prognostic algorithms that are informative for certain clinical groups of BC patients is a promising area of research.

Хроническое воспаление — один из признанных факторов, способствующих возникновению и прогрессии злокачественных новообразований. На системном уровне хронический воспалительный процесс сопровождается изменением содержания в крови медиаторов воспаления и гематологических показателей периферической крови. Соотношение количества определенных популяций клеток крови у онкологических больных, по данным многочисленных клинических исследований, является независимым фактором прогноза при злокачественных опухолях различных локализаций. Настоящий обзор посвящен гематологическим показателям системной воспалительной реакции (СВР) при раке молочной железы (РМЖ). В статье описаны свойства клеток периферической крови (нейтрофилов, лимфоцитов, моноцитов, тромбоцитов), определяющие их связь с развитием онкологической патологии, и способы оценки выраженности СВР с использованием гематологических показателей (индексы NLR, PLR, LMR и др.). Представлен сравнительный анализ данных о взаимосвязи этих показателей с клинико-морфологическими особенностями РМЖ, выживаемостью больных и ответом опухоли на химиотерапию. Рассмотрены комбинированные алгоритмы, включающие клинико-морфологические факторы и гематологические индексы, которые предлагаются для повышения качества прогностической оценки. Накопленные на сегодняшний день данные свидетельствуют о том, что гематологические индексы, отражающие активность СВР у больных РМЖ, могут служить дополнительными независимыми факторами прогноза заболевания. Разработка прогностических алгоритмов, информативных для определенных клинических групп больных РМЖ, является перспективным направлением исследований.

breast cancersystemic inflammatory responsehematological markersprognosisрак молочной железысистемная воспалительная реакциягематологические индексыпрогнозФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииNational Medical Research Radiological Center of the Ministry of Health of the Russian FederationGreten FR, Grivennikov SI. Inflammation and сancer: Triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi: https://doi.org/10.1016/j.immuni.2019.06.025Hibino S, Kawazoe T, Kasahara H, et al. Inflammation-induced tumorigenesis and metastasis. Int J Mol Sci. 2021;22(11):5421. doi: https://doi.org/10.3390/ijms22115421Salemme V, Centonze G, Cavallo F, et al. The crosstalk between tumor cells and the immune microenvironment in breast cancer: Implications for immunotherapy. Front Oncol. 2021;11:610303. doi: https://doi.org/10.3389/fonc.2021.610303Brenner DR, Scherer D, Muir K, et al. A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1729–1751. doi: https://doi.org/10.1158/1055-9965.EPI-14-0064Guner A, Kim HI. Biomarkers for evaluating the inflammation status in patients with cancer. J Gastric Cancer. 2019;19(3):254–277. doi: https://doi.org/10.5230/jgc.2019.19.e29Dolan RD, Lim J, McSorley ST, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017;7(1):16717. doi: https://doi.org/10.1038/s41598-017-16955-5Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271. doi: https://doi.org/10.1146/annurev-immunol-031210-101324Kotoula V, Chatzopoulos K, Lakis S, et al. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016;7(4):5074–5087. doi: https://doi.org/10.18632/oncotarget.6231Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51. doi: https://doi.org/10.1016/j.critrevonc.2018.01.003Emile G, Penager S, Levy C, et al. Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncol Lett. 2022;23(1):25. doi: https://doi.org/10.3892/ol.2021.13143Lee KH, Kim EY, Yun JS, et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer. BMC Cancer. 2018;18(1):938. doi: https://doi.org/10.1186/s12885-018-4832-5Yoon CI, Park S, Cha YJ, et al. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. Breast. 2020;50:141–148. doi: https://doi.org/10.1016/j.breast.2019.09.013Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173. doi: https://doi.org/10.1186/s13045-021-01187-yHajizadeh F, Aghebati Maleki L, Alexander M, et al. Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. Life Sci. 2021;264:118699. doi: https://doi.org/10.1016/j.lfs.2020.118699Margraf A, Zarbock A. Platelets in inflammation and resolution. J Immunol. 2019;203(9):2357–2367. doi: https://doi.org/10.4049/jimmunol.1900899Plantureux L, Mège D, Crescence L, et al. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel). 2018;10(11):441. doi: https://doi.org/10.3390/cancers10110441Ward MP, Kane LE, Norris LA, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer. 2021;20(1):59. doi: https://doi.org/10.1186/s12943-021-01347-1Chen Y, Song Y, Du W et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. doi: https://doi.org/10.1186/s12929-019-0568-zGuo S, Chen X, Guo C, et al. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. Expert Rev Mol Med. 2022;24:e17. doi: https://doi.org/10.1017/erm.2022.8Kiss M, Caro AA, Raes G, et al. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10:1399. doi: https://doi.org/10.3389/fonc.2020.01399Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi: https://doi.org/10.1093/jnci/dju124Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced cancer: Review and meta-analysis. Clin Chim Acta. 2018;483:48–56. doi: https://doi.org/10.1016/j.cca.2018.04.023Mao Y, Chen D, Duan S, et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int. 2018;18:201. doi: https://doi.org/10.1186/s12935-018-0698-5Zhang F, Huang M, Zhou H, et al. A nomogram to predict the pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple laboratory indicators. Ann Surg Oncol. 2019;26(12):3912–3919. doi: https://doi.org/10.1245/s10434-019-07655-7Zhu J, Jiao D, Zhao Y, et al. Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients. Sci Rep. 2021;11(1):1350. doi: https://doi.org/10.1038/s41598-020-80037-2Ueno A, Maeda R, Kin T, et al. Utility of the absolute lymphocyte count and neutrophil/lymphocyte ratio for predicting survival in patients with metastatic breast cancer on eribulin: A real-world observational study. Chemotherapy. 2019;64(5–6):259–269. doi: https://doi.org/10.1159/000507043Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–139. doi: https://doi.org/10.1016/j.pharmthera.2013.09.004Nakamoto S, Ikeda M, Kubo S, et al. The systemic immune markers at diagnosis can predict the survival benefit in advanced breast cancer. Cancer Diagn Progn. 2021;1(5):471–478. doi: https://doi.org/10.21873/cdp.10063Kim D, Bae SJ, Ahn SG, et al. RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis. Breast Cancer Res Treat. 2022;193(3):637–647. doi: https://doi.org/10.1007/s10549-022-06601-8Ma Y, Zhang J, Chen X. Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Cancer Manag Res. 2021;13:1571–1580. doi: https://doi.org/10.2147/CMAR.S292048Deng JP, Hua X, Long ZQ, et al. Prognostic value of skeletal muscle index and monocyte-to-lymphocyte ratio for lymph node-positive breast cancer patients after mastectomy. Ann Transl Med. 2019;7(23):775. doi: https://doi.org/10.21037/atm.2019.11.37Truffi M, Piccotti F, Albasini S, et al. Preoperative systemic inflammatory biomarkers are independent predictors of disease recurrence in ER+ HER2- early breast cancer. Front Oncol. 2021;11:773078. doi: https://doi.org/10.3389/fonc.2021.773078Moldoveanu D, Pravongviengkham V, Best G, et al. Dynamic neutrophil-to-lymphocyte ratio: A novel prognosis measure for triple-negative breast cancer. Ann Surg Oncol. 2020;27(10):4028–4034. doi: https://doi.org/10.1245/s10434-020-08302-2Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: A systematic review. Cancers (Basel). 2020;12(4):958. doi: https://doi.org/10.3390/cancers12040958Azab B, Camacho-Rivera M, Taioli E. Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects. PLoS One. 2014;9(11):e112361. doi: https://doi.org/10.1371/journal.pone.0112361Lin BD, Hottenga JJ, Abdellaoui A, et al. Causes of variation in the neutrophil-lymphocyte and platelet-lymphocyte ratios: a twin-family study. Biomark Med. 2016;10(10):1061–1072. doi: https://doi.org/10.2217/bmm-2016-0147Howard R, Scheiner A, Kanetsky PA, et al. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. Ann Epidemiol. 2019;38:11–21.e6. doi: https://doi.org/10.1016/j.annepidem.2019.07.015Jiang L, Fang J, Ding J. High systemic immune-inflammation index predicts poor survival in patients with human epidermal growth factor receptor-2 positive breast cancer receiving adjuvant trastuzumab. Cancer Manag Res. 2020;12:475–484. doi: https://doi.org/10.2147/CMAR.S231444He Q, Li JY, Ren Q-L. Efficacy of neoadjuvant single or dual anti-HER-2 therapy combined with chemotherapy in patients with HER-2-positive breast cancer: A single-center retrospective study. Asian Pac J Cancer Prev. 2021;22(5):1467–1475. doi: https://doi.org/10.31557/APJCP.2021.22.5.1467Ligorio F, Fucà G, Zattarin E, et al. The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel). 2021;13(8):1964. doi: https://doi.org/10.3390/cancers13081964Deng Y, Li W, Liu X, et al. The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer. Medicine (Baltimore). 2020;99(18):e18755. doi: https://doi.org/10.1097/MD.0000000000018755Chen L, Kong X, Wang Z, et al. Pretreatment systemic inflammation response index in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Cancer Manag Res. 2020;12:1543–1567. doi: https://doi.org/10.2147/CMAR.S235519Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662. doi: https://doi.org/10.1038/s41598-021-94184-7Jiang C, Zhang S, Qiao K, et al. The pretreatment systemic inflammation response index as a useful prognostic factor is better than lymphocyte to monocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy. Clin Breast Cancer. 2022;22(5):424–438. doi: https://doi.org/10.1016/j.clbc.2022.03.003Lin F, Zhang LP, Xie SY, et al. Pan-immune-inflammation value: A new prognostic index in operative breast cancer. Front Oncol. 2022;12:830138. doi: https://doi.org/10.3389/fonc.2022.830138Wang P, Yue W, Li W, et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer. Cancer Manag Res. 2019;11:813–819. doi: https://doi.org/10.2147/CMAR.S185890Hu RJ, Liu Q, Ma JY, et al. Preoperative lymphocyte-to-monocyte ratio predicts breast cancer outcome: A meta-analysis. Clin Chim Acta. 2018;484:1–6. doi: https://doi.org/10.1016/j.cca.2018.05.031Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135–4148. doi: https://doi.org/10.1002/cam4.2281Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224. doi: https://doi.org/10.1186/s12935-020-01308-6Li W, Ma G, Deng Y, et al. Systemic immune-inflammation index is a prognostic factor for breast cancer patients after curative resection. Front Oncol. 2021;11:570208. doi: https://doi.org/10.3389/fonc.2021.570208Zhu M, Chen L, Kong X, et al. The systemic immune-inflammation index is an independent predictor of survival in breast cancer patients. Cancer Manag Res. 2022;14:775–820. doi: https://doi.org/10.2147/CMAR.S346406Hua X, Long ZQ, Huang X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer. Curr Probl Cancer. 2020;44(4):100560. doi: https://doi.org/10.1016/j.currproblcancer.2020.100560Wang L, Zhou Y, Xia S, et al. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. Cancer Biomark. 2020;28(4):537–547. doi: https://doi.org/10.3233/CBM-201682Dong J, Sun Q, Pan Y, et al. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. BMC Cancer. 2021;21(1):700. doi: https://doi.org/10.1186/s12885-021-08458-4Eren T, Karacin C, Ucar G, et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients. Medicine (Baltimore). 2020;99(22):e20346. doi: https://doi.org/10.1097/MD.0000000000020346Boér K, Kahán Z, Landherr L, et al. Pathologic complete response rates after neoadjuvant pertuzumab and trastuzumab with chemotherapy in early stage HER2-positive breast cancer — increasing rates of breast conserving surgery: A real-world experience. Pathol Oncol Res. 2021;27:1609785. doi: https://doi.org/10.3389/pore.2021.1609785Tang L, Shu X, Tu G. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study. World J Surg Oncol. 2022;20(1):27. doi: https://doi.org/10.1186/s12957-022-02492-7Li X, Tan Q, Li H, Yang X. Predictive value of pretreatment peripheral neutrophil-to-lymphocyte ratio for response to neoadjuvant chemotherapy and breast cancer prognosis. Cancer Manag Res. 2021;13:5889–5898. doi: https://doi.org/10.2147/CMAR.S313123Muñoz-Montaño W, Cabrera-Galeana P, Alvarado-Miranda A, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in different phenotypes of locally advanced breast cancer during neoadjuvant systemic treatment. Clin Breast Cancer. 2020;20(4):307–316.e1. doi: https://doi.org/10.1016/j.clbc.2019.12.011Jiang C, Lu Y, Zhang S, et al. Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. Biomed Res Int. 2020;2020:7961568. doi: https://doi.org/10.1155/2020/7961568Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, et al. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS One. 2018;13(11):e0207224. doi: https://doi.org/10.1371/journal.pone.0207224Kaytaz Tekyol K, Gurleyik G, Aktaş A, et al. Pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: The relationship between inflammatory biomarkers and molecular subtypes. Cureus. 2021;13(4):e14774. doi: https://doi.org/10.7759/cureus.14774Hu Y, Wang S, Ding N, et al. Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal B-like (HER2-) breast cancer. Clin Breast Cancer. 2020;20(4):e403–e409. doi: https://doi.org/10.1016/j.clbc.2020.01.008Corbeau I, Thezenas S, Maran-Gonzalez A, et al. Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy. Cancers (Basel). 2020;12(9):2666. doi: https://doi.org/10.3390/cancers12092666Kim JY, Jung EJ, Kim JM, et al. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer. 2020;20(1):1206. doi: https://doi.org/10.1186/s12885-020-07700-9Meng X, Wang X, Jiang C, et al. Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer. Transl Oncol. 2022;18:101355. doi: https://doi.org/10.1016/j.tranon.2022.101355Goto W, Kashiwagi S, Asano Y, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer. 2018;18(1):1137. doi: https://doi.org/10.1186/s12885-018-5051-9Song X, Ma J, Zhang H, et al. Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Gland Surg. 2020;9(5):1450–1468. doi: https://doi.org/10.21037/gs-20-622Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol. 2018;20(4):476–483. doi: https://doi.org/10.1007/s12094-017-1732-0Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol. 2021;225(4):392–396. doi: https://doi.org/10.1016/j.ajog.2021.04.217Lim B, Woodward WA, Wang X, et al. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018;18(8):485–499. doi: https://doi.org/10.1038/s41568-018-0010-yVan Berckelaer C, Van Geyt M, Linders S, et al. A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer. Breast. 2020;53:212–220. doi: https://doi.org/10.1016/j.breast.2020.08.006Al Jarroudi O, El Bairi K, Abda N, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. Biomark Med. 2021;15(14):1289–1298. doi: https://doi.org/10.2217/bmm-2020-0717Takada K, Kashiwagi S, Asano Y, et al. Clinical evaluation of dynamic monitoring of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in primary endocrine therapy for advanced breast cancer. Anticancer Res. 2019;39(10):5581–5588. doi: https://doi.org/10.21873/anticanres.13752Myojin M, Horimoto Y, Ito M, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer. 2020;27(4):732–738. doi: https://doi.org/10.1007/s12282-020-01069-0Orlandini LF, Pimentel FF, Andrade JM, et al. Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients. Braz J Med Biol Res. 2021;54(10):e11409. doi: https://doi.org/10.1590/1414-431X2021e11409Takamizawa S, Shimoi T, Satomi-Tsushita N, et al. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study. BMC Cancer. 2022;22(1):64. doi: https://doi.org/10.1186/s12885-021-09112-9Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi: https://doi.org/10.1371/journal.pone.0200936Huszno J, Kolosza Z. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients. Oncol Lett. 2019;18(6):6275–6283. doi: https://doi.org/10.3892/ol.2019.10966Wang Y, Huang G, Li Z. Prognostic significance of inflammatory biomarkers in patients with breast cancer skeletal metastases. Cancer Manag Res. 2020;12:11463–11475. doi: https://doi.org/10.2147/CMAR.S277291Ji H, Xuan Q, Yan C, et al. The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy. Oncotarget. 2016;7(23):34881–34889. doi: https://doi.org/10.18632/oncotarget.8993Yin Y, Zhang Y, Li L, et al. Prognostic value of pretreatment lymphocyte-to-monocyte ratio and development of a nomogram in breast cancer patients. Front Oncol. 2021;11:650980. doi: https://doi.org/10.3389/fonc.2021.650980Zhang Z, Lin Q, Chen Y, et al. Prognostic evaluation of metastasis-related lymphocyte/monocyte ratio in stage I-III breast cancer receiving chemotherapy. Front Oncol. 2022;11:782383. doi: https://doi.org/10.3389/fonc.2021.782383Gerratana L, Basile D, Toffoletto B, et al. Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Sci Rep. 2020;10(1):7010. doi: https://doi.org/10.1038/s41598-020-63291-2Koh YW, Lee HJ, Ahn JH, et al. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour Biol. 2014;35(10):9823–9830. doi: https://doi.org/10.1007/s13277-014-2282-5Zenan H, Zixiong L, Zhicheng Y, et al. Clinical prognostic evaluation of immunocytes in different molecular subtypes of breast cancer. J Cell Physiol. 2019;234(11):20584–20602. doi: https://doi.org/10.1002/jcp.28662Tiainen S, Rilla K, Hämäläinen K, et al. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Breast Cancer Res Treat. 2021;185(1):63–72. doi: https://doi.org/10.1007/s10549-020-05925-7Moon G, Noh H, Cho IJ, et al. Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence. Breast Cancer. 2020;27(1):54–61. doi: https://doi.org/10.1007/s12282-019-00994-zKim KM, Choi HS, Noh H, et al. Neutrophil to lymphocyte ratio after treatment completion as a potential predictor of survival in patients with triple-negative breast cancer. J Breast Cancer. 2021;24(5):443–454. doi: https://doi.org/10.4048/jbc.2021.24.e43Dan J, Tan J, Huang J, et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer. 2020;27(5):982–988. doi: https://doi.org/10.1007/s12282-020-01096-xZheng Y, Wu C, Yan H, et al. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study. Clin Chim Acta. 2020;506:110–121. doi: https://doi.org/10.1016/j.cca.2020.03.011Polley M-YC, Leon-Ferre RA, Leung S, et al. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021;185(3):557–566. doi: https://doi.org/10.1007/s10549-020-06030-5Hua X, Duan F, Zhai W, et al. A novel inflammatory-nutritional prognostic scoring system for patients with early-stage breast cancer. J Inflamm Res. 2022;15:381–394. doi: https://doi.org/10.2147/JIR.S338421